The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Liver Cirrhosis

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Liver Cirrhosis


Psychiatry related information on Liver Cirrhosis


High impact information on Liver Cirrhosis


Chemical compound and disease context of Liver Cirrhosis


Biological context of Liver Cirrhosis


Anatomical context of Liver Cirrhosis


Gene context of Liver Cirrhosis

  • Thus, HGF gene therapy may be potentially useful for the treatment of patients with liver cirrhosis, which is otherwise fatal and untreatable by conventional therapy [12].
  • SOCS1 is a suppressor of liver fibrosis and hepatitis-induced carcinogenesis [13].
  • The mean mRNA ratio of group II PLA2/GAPDH was increased in liver tissue by 126% (P < 0.001) and in kidney tissue by 263% (P < 0.006) following induction of liver cirrhosis [28].
  • In addition, only 1 of 20 patients with hepatitis plus liver cirrhosis displayed elevated levels of serum GPC3 [29].
  • Smad7 prevents activation of hepatic stellate cells and liver fibrosis in rats [30].

Analytical, diagnostic and therapeutic context of Liver Cirrhosis


  1. A novel cytoplasmic protein with RNA-binding motifs is an autoantigen in human hepatocellular carcinoma. Zhang, J.Y., Chan, E.K., Peng, X.X., Tan, E.M. J. Exp. Med. (1999) [Pubmed]
  2. Molecular basis of polymorphisms of human complement component C3. Botto, M., Fong, K.Y., So, A.K., Koch, C., Walport, M.J. J. Exp. Med. (1990) [Pubmed]
  3. Liver collagen synthesis in murine schistosomiasis. Dunn, M.A., Rojkind, M., Warren, K.S., Hait, P.K., Rifas, L., Seifter, S. J. Clin. Invest. (1977) [Pubmed]
  4. Causes and management of intestinal failure in children. Goulet, O., Ruemmele, F. Gastroenterology (2006) [Pubmed]
  5. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Bruix, J., Barrera, J.M., Calvet, X., Ercilla, G., Costa, J., Sanchez-Tapias, J.M., Ventura, M., Vall, M., Bruguera, M., Bru, C. Lancet (1989) [Pubmed]
  6. Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Benhamou, Y., Di Martino, V., Bochet, M., Colombet, G., Thibault, V., Liou, A., Katlama, C., Poynard, T. Hepatology (2001) [Pubmed]
  7. Anti-TGF-beta strategies for the treatment of chronic liver disease. Breitkopf, K., Haas, S., Wiercinska, E., Singer, M.V., Dooley, S. Alcohol. Clin. Exp. Res. (2005) [Pubmed]
  8. Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans. Hillebrandt, S., Wasmuth, H.E., Weiskirchen, R., Hellerbrand, C., Keppeler, H., Werth, A., Schirin-Sokhan, R., Wilkens, G., Geier, A., Lorenzen, J., Köhl, J., Gressner, A.M., Matern, S., Lammert, F. Nat. Genet. (2005) [Pubmed]
  9. Theophylline disposition in patients with hepatic cirrhosis. Piafsky, K.M., Sitar, D.S., Rangno, R.E., Ogilvie, R.I. N. Engl. J. Med. (1977) [Pubmed]
  10. RNA interference targeting Fas protects mice from fulminant hepatitis. Song, E., Lee, S.K., Wang, J., Ince, N., Ouyang, N., Min, J., Chen, J., Shankar, P., Lieberman, J. Nat. Med. (2003) [Pubmed]
  11. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Bátkai, S., Járai, Z., Wagner, J.A., Goparaju, S.K., Varga, K., Liu, J., Wang, L., Mirshahi, F., Khanolkar, A.D., Makriyannis, A., Urbaschek, R., Garcia, N., Sanyal, A.J., Kunos, G. Nat. Med. (2001) [Pubmed]
  12. Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Ueki, T., Kaneda, Y., Tsutsui, H., Nakanishi, K., Sawa, Y., Morishita, R., Matsumoto, K., Nakamura, T., Takahashi, H., Okamoto, E., Fujimoto, J. Nat. Med. (1999) [Pubmed]
  13. SOCS1 is a suppressor of liver fibrosis and hepatitis-induced carcinogenesis. Yoshida, T., Ogata, H., Kamio, M., Joo, A., Shiraishi, H., Tokunaga, Y., Sata, M., Nagai, H., Yoshimura, A. J. Exp. Med. (2004) [Pubmed]
  14. Coexpression of the collagen-binding stress protein HSP47 gene and the alpha 1(I) and alpha 1(III) collagen genes in carbon tetrachloride-induced rat liver fibrosis. Masuda, H., Fukumoto, M., Hirayoshi, K., Nagata, K. J. Clin. Invest. (1994) [Pubmed]
  15. Insulin resistance in liver cirrhosis. Positron-emission tomography scan analysis of skeletal muscle glucose metabolism. Selberg, O., Burchert, W., vd Hoff, J., Meyer, G.J., Hundeshagen, H., Radoch, E., Balks, H.J., Müller, M.J. J. Clin. Invest. (1993) [Pubmed]
  16. Downregulation of the male-specific hepatic microsomal steroid 16 alpha-hydroxylase, cytochrome P-450UT-A, in rats with portal bypass. Relevance to estradiol accumulation and impaired drug metabolism in hepatic cirrhosis. Cantrill, E., Murray, M., Mehta, I., Farrell, G.C. J. Clin. Invest. (1989) [Pubmed]
  17. Reduced peripheral conversion of thyroxine to triiodothyronine in patients with hepatic cirrhosis. Nomura, S., Pittman, C.S., Chambers, J.B., Buck, M.W., Shimizu, T. J. Clin. Invest. (1975) [Pubmed]
  18. Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. Wiest, R., Das, S., Cadelina, G., Garcia-Tsao, G., Milstien, S., Groszmann, R.J. J. Clin. Invest. (1999) [Pubmed]
  19. Impaired hepatic handling and processing of lysophosphatidylcholine in rats with liver cirrhosis. Angelico, M., Alvaro, D., Cantafora, A., Masella, R., Gaudio, E., Gandin, C., Ginanni Corradini, S., Ariosto, F., Riggio, O., Capocaccia, L. Gastroenterology (1991) [Pubmed]
  20. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. Nelson, D.R., Lauwers, G.Y., Lau, J.Y., Davis, G.L. Gastroenterology (2000) [Pubmed]
  21. Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners. Radaeva, S., Sun, R., Jaruga, B., Nguyen, V.T., Tian, Z., Gao, B. Gastroenterology (2006) [Pubmed]
  22. The -2518 promotor polymorphism in the MCP-1 gene is not associated with liver cirrhosis in chronic hepatitis C virus infection. Glas, J., Török, H.P., Tonenchi, L., Schiemann, U., Folwaczny, C. Gastroenterology (2004) [Pubmed]
  23. Experimental liver cirrhosis induced by alcohol and iron. Tsukamoto, H., Horne, W., Kamimura, S., Niemelä, O., Parkkila, S., Ylä-Herttuala, S., Brittenham, G.M. J. Clin. Invest. (1995) [Pubmed]
  24. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Galli, A., Crabb, D.W., Ceni, E., Salzano, R., Mello, T., Svegliati-Baroni, G., Ridolfi, F., Trozzi, L., Surrenti, C., Casini, A. Gastroenterology (2002) [Pubmed]
  25. Action of the triglycyl hormonogen of vasopressin (glypressin) in patients with liver cirrhosis and bleeding esophageal varices. Vosmík, J., Jedlicka, K., Mulder, J.L., Cort, J.H. Gastroenterology (1977) [Pubmed]
  26. Cytomegalovirus reactivation and tumour necrosis factor. Döcke, W.D., Prösch, S., Fietze, E., Kimel, V., Zuckermann, H., Klug, C., Syrbe, U., Krüger, D.H., von Baehr, R., Volk, H.D. Lancet (1994) [Pubmed]
  27. Ethanol, the liver, and the gastrointestinal tract. Geokas, M.C., Lieber, C.S., French, S., Halsted, C.H. Ann. Intern. Med. (1981) [Pubmed]
  28. Liver cirrhosis induces renal and liver phospholipase A2 activity in rats. Vishwanath, B.S., Frey, F.J., Escher, G., Reichen, J., Frey, B.M. J. Clin. Invest. (1996) [Pubmed]
  29. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Capurro, M., Wanless, I.R., Sherman, M., Deboer, G., Shi, W., Miyoshi, E., Filmus, J. Gastroenterology (2003) [Pubmed]
  30. Smad7 prevents activation of hepatic stellate cells and liver fibrosis in rats. Dooley, S., Hamzavi, J., Breitkopf, K., Wiercinska, E., Said, H.M., Lorenzen, J., Ten Dijke, P., Gressner, A.M. Gastroenterology (2003) [Pubmed]
  31. Cellular distribution of transforming growth factor-beta 1 and procollagen types I, III, and IV transcripts in carbon tetrachloride-induced rat liver fibrosis. Nakatsukasa, H., Nagy, P., Evarts, R.P., Hsia, C.C., Marsden, E., Thorgeirsson, S.S. J. Clin. Invest. (1990) [Pubmed]
  32. Expression of activin A is increased in cirrhotic and fibrotic rat livers. Sugiyama, M., Ichida, T., Sato, T., Ishikawa, T., Matsuda, Y., Asakura, H. Gastroenterology (1998) [Pubmed]
  33. Correlations of chronic hepatitis B virus infection and cigarette smoking with elevated expression of neu oncoprotein in the development of hepatocellular carcinoma. Yu, M.W., Chen, C.J., Luo, J.C., Brandt-Rauf, P.W., Carney, W.P., Santella, R.M. Cancer Res. (1994) [Pubmed]
  34. A new tumor-associated antigen useful for serodiagnosis of hepatocellular carcinoma, defined by monoclonal antibody KM-2. Kumagai, Y., Chiba, J., Sata, T., Ohtaki, S., Mitamura, K. Cancer Res. (1992) [Pubmed]
  35. Plasma levels of pipecolic acid in patients with chronic liver disease. Kawasaki, H., Hori, T., Nakajima, M., Takeshita, K. Hepatology (1988) [Pubmed]
WikiGenes - Universities